Management of emerging multidrug-resistant tuberculosis in a low-prevalence setting. (May 2015)

• Record Type: Journal Article
• Authors: Catho, G.; Couraud, S.; Grard, S.; Bouaziz, A.; Sénéchal, A.; Valour, F.; Perpoint, T.; Braun, E.; Biron, F.; Ferry, T.; Chidiac, C.; Freymond, N.; Perrot, E.; Souquet, P.-J.; Maury, J.-M.; Tronc, F.; Veziris, N.; Lina, G.; Dumitrescu, O.; Ader, F.
• Is Part Of: Clinical microbiology and infection. Volume 21:Number 5(2015:May)
• Page Start: 472.e7
• Page End: 472.e10
• Publication Date: 2015-05
• Subjects: Bedaquiline -- MDR TB surgery -- multidrug-resistant tuberculosis -- Mycobacterium tuberculosis -- negative-pressure ventilation room; Medical microbiology -- Periodicals; Diagnostic microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.01
• DOI: 10.1016/j.cmi.2014.12.022
• Languages: English
• ISSNs: 1198-743X

Abstract

Abstract: Multidrug-resistant (MDR) tuberculosis (TB) is an emerging concern in communities with a low TB prevalence and a high standard of public health. Twenty-three consecutive adult MDR TB patients who were treated at our institution between 2007 and 2013 were reviewed for demographic characteristics and anti-TB treatment management, which included surgical procedures and long-term patient follow-up. This report of our experience emphasizes the need for an individualized approach as MDR TB brings mycobacterial disease management to a higher level of expertise, and for a balance to be found between international current guidelines and patient-tailored treatment strategies.